<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02415010</url>
  </required_header>
  <id_info>
    <org_study_id>NV-PMK-1401</org_study_id>
    <nct_id>NCT02415010</nct_id>
  </id_info>
  <brief_title>Post-Market Clinical Follow-Up Study to Confirm Clinical Performance and Safety of the Codman Enterprise® 2 Vascular Reconstruction Device in the Endovascular Treatment of Intracranial Aneurysms</brief_title>
  <acronym>SUNRISE-2</acronym>
  <official_title>A Post-Market Clinical Follow-Up Study to Confirm Clinical Performance and Safety of the Codman Enterprise® 2 Vascular Reconstruction Device in the Endovascular Treatment of Intracranial Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Codman &amp; Shurtleff</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Codman &amp; Shurtleff</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Post-Market Clinical Follow-up (PMCF) is to confirm the performance and
      safety of the Codman Enterprise® 2 when used in conjunction with endovascular coil
      embolization of ruptured or non-ruptured intracranial aneurysms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Major Ipsilateral Stroke and/or Death due to related neurological event in subjects with a non-ruptured aneurysm.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Successful Aneurysm treatment without retreatment</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Successful Aneurysm treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Aneurysm Recanalization</measure>
    <time_frame>6 &amp; 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Retreatment</measure>
    <time_frame>6 &amp; 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New Neurological Deficits</measure>
    <time_frame>30 Days, 6 &amp; 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Ipsilateral Stroke and/or Death due to related neurological event</measure>
    <time_frame>30 Days and 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Parent Vessel Thrombosis</measure>
    <time_frame>6 &amp; 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Parent Vessel Stenosis</measure>
    <time_frame>6 &amp; 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stent Movement/Migration</measure>
    <time_frame>6 &amp; 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>6 &amp; 12 Months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Enterprise 2 Vascular Reconstruction Device</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with both ruptured and non-ruptured aneurysms will be enrolled into the study,
        with a parent vessel diameter of ≥ 2.0 mm and ≤ 4 mm
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject ≥ 18 years old.

          2. Subjects with non-ruptured or ruptured intracranial aneurysm that is referred for
             endovascular treatment.

          3. Parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm.

          4. Subject understands the nature of the procedure and provides voluntary written
             informed consent in accordance with the requirements of this study protocol.

          5. Subject is willing to participate in the telephone follow-ups and to return to the
             investigational site for the post-procedure follow-up evaluations.

        Exclusion Criteria:

          1. Angiogram demonstrating that the aneurysm is not appropriate for endovascular
             treatment (i.e.: severe intracranial vessel tortuosity, stenosis, intracranial
             vasospasm not responsive to medical therapy).

          2. Mycotic or traumatic aneurysm.

          3. Arteriovenous malformation (AVM) in the territory of the target aneurysm.

          4. Two or more aneurysms (&gt;2mm) in associated distribution.

          5. Hunt and Hess Scale (HHS) of IV or V at inclusion for subject with ruptured aneurysms.

          6. Life expectancy of less than 6 months as determined by the treating physician.

          7. A planned staged procedure (i.e. a procedure where entire treatment with the devices
             (e.g. coils/stents) is completed over separate sessions).

          8. Previous neuro-interventional or neuro-surgical procedure of any kind within 30 days
             prior to the study procedure.

          9. Intracranial mass (tumor, abscess, or other infection), or undergoing radiation
             therapy for carcinoma or sarcoma of the head or neck region.

         10. Unsuitable for the antithrombotic and/or anticoagulant therapies

         11. Serum creatinine level &gt; 2.5 mg/dl within 7 days prior to index procedure

         12. Known hypersensitivity or allergies to cobalt, nitinol metal, nickel, or sensitivity
             to contrast media,

         13. Evidence of an acute myocardial infarction (MI) within 30 days prior to the index
             procedure.

         14. Uncontrolled atrial fibrillation or known cardiac disorders likely to be associated
             with cardioembolic symptoms.

         15. Subject is pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J FIEHLER, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnaud NICOLAS, PhD</last_name>
    <phone>+41 327 204 460</phone>
    <email>anicolas@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helios Klinikum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M HARTMANN, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätslklinikum der Ruhr Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S FISCHER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Eppendorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J FIEHLER, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Atona</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B ECKERT, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schl.-Holst. Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P SCHRAMM, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J OLIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital-Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Gralla, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zsolt Kulcsar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spire Leeds Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tony GODDARD, MB PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital of Romford</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S DERAKHSHANI, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

